{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for monomethyl root_names_stdName in Standardized Name (approximate match)
Status:
US Approved Rx
(1994)
Source:
BLA103411
(1994)
Source URL:
First approved in 1994
Source:
BLA103411
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:becotatug vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:ozuriftamab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02988817: Phase 1/Phase 2 Interventional Completed Ovarian Cancer
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02202759: Phase 2 Interventional Terminated Adenocarcinoma of the Stomach
(2014)
Source URL:
Class:
PROTEIN
Status:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01691898: Phase 1/Phase 2 Interventional Completed Follicular Lymphoma
(2012)
Source URL:
Class:
PROTEIN
Status:
US Previously Marketed
Source:
ADAGEN by LEADIANT BIOSCI INC
(1990)
Source URL:
First approved in 1990
Source:
ADAGEN by LEADIANT BIOSCI INC
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA761158
(2020)
Source URL:
First approved in 2020
Source:
BLA761158
Source URL:
Class:
PROTEIN
